CLOV vs ELV

For growth investors, Clover Health Investments, Corp.

(CLOV) is the stronger pick with 40. 3% revenue growth year-over-year, versus 12. 6% for Elevance Health Inc. (ELV). Elevance Health Inc. (ELV) offers the better valuation at 14. 9x trailing P/E (14. 0x forward), making it the more compelling value choice. Analysts rate Elevance Health Inc. (ELV) a "Buy" — based on 37 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Elevance Health Inc.

is actually cheaper at 14. 0x.

Over the past 5 years, Elevance Health Inc.

(ELV) delivered a total return of +4. 0%, compared to -67. 4% for Clover Health Investments, Corp. (CLOV). Over 10 years, the gap is even starker: ELV returned +206. 0% versus CLOV's -73. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Elevance Health Inc.

(ELV) is the lower-risk stock at 0. 46β versus Clover Health Investments, Corp. 's 1. 22β — meaning CLOV is approximately 164% more volatile than ELV relative to the S&P 500.

By revenue growth (latest reported year), Clover Health Investments, Corp.

(CLOV) is pulling ahead at 40. 3% versus 12. 6% for Elevance Health Inc. (ELV). On earnings-per-share growth, the picture is similar: Elevance Health Inc. grew EPS -2. 2% year-over-year, compared to -93. 6% for Clover Health Investments, Corp.. Over a 3-year CAGR, CLOV leads at 20. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Elevance Health Inc.

(ELV) is the more profitable company, earning 2. 8% net margin versus -4. 4% for Clover Health Investments, Corp. — meaning it keeps 2. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ELV leads at 4. 1% versus -4. 4% for CLOV. At the gross margin level — before operating expenses — ELV leads at 25. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Elevance Health Inc.

(ELV) trades at 14. 0x forward P/E versus 62. 6x for Clover Health Investments, Corp. — 48. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CLOV: 24. 3% to $3. 33.

In this comparison, ELV (1.

8% yield) pays a dividend. CLOV does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Elevance Health Inc.

(ELV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 46), 1. 8% yield, +206. 0% 10Y return). Both have compounded well over 10 years (ELV: +206. 0%, CLOV: -73. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: CLOV is a small-cap high-growth stock; ELV is a mid-cap deep-value stock. ELV pays a dividend while CLOV does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.